What is the minimal time after angioplasty and placement of a drug eluting stent that dual antiplatelet therapy should be continued before considering stopping it for elective surgery?

What is the minimal time after angioplasty and placement of a drug eluting stent that dual antiplatelet therapy should be continued before considering stopping it for elective surgery?

• A. 3 months
• B. 6 months
• C. 1 year
• D. 18 months

Answer: (C)

After placing a drug-eluting stent, the risk of stent thrombosis remains elevated as the vessel heals and the stent’s surface endothelializes. The antiproliferative drugs and polymer coating on DES sleeves delay this healing, so keeping dual antiplatelet therapy active for a full year substantially reduces the risk of thrombotic events. Therefore, the minimal time to consider stopping dual antiplatelet therapy for elective noncardiac surgery is about 12 months. Shorter durations (3 or 6 months) are generally not sufficient after DES, while extending beyond a year may be considered only if bleeding risk is very low and thrombosis risk remains high, but the baseline minimal period is 12 months. If surgery is urgent, management depends on balancing thrombosis and bleeding risks, with aspirin typically continued and the P2Y12 inhibitor paused only when feasible.

After placing a drug-eluting stent, the risk of stent thrombosis remains elevated as the vessel heals and the stent’s surface endothelializes. The antiproliferative drugs and polymer coating on DES sleeves delay this healing, so keeping dual antiplatelet therapy active for a full year substantially reduces the risk of thrombotic events. Therefore, the minimal time to consider stopping dual antiplatelet therapy for elective noncardiac surgery is about 12 months. Shorter durations (3 or 6 months) are generally not sufficient after DES, while extending beyond a year may be considered only if bleeding risk is very low and thrombosis risk remains high, but the baseline minimal period is 12 months. If surgery is urgent, management depends on balancing thrombosis and bleeding risks, with aspirin typically continued and the P2Y12 inhibitor paused only when feasible.